Vaxcyte, Inc.

NASDAQ: PCVX · Healthcare · Biotechnology

PublicHQ San Carlos, CA · San MateoCIK 0001649094Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 62DQ —GM —SS 68

v0.1 · 35/100 weight · pillars only

↑ market scale, Altman-Z · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$766.6M

Employees

507

as of 2026-08-06

Market cap

$8.1B

as of 2026-08-06

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$766.6M-$766.6M2025

Operating income-$923.7M-$923.7M2025

Total assets$3.0B$3.0B2025

Liabilities$317.2M$317.2M2025

Equity$2.7B$2.7B2025

Revenue by segment

Filed disclosures · FY2021

By product

Pneumococcal Conjugate Vaccine100%

By geography

Not disclosed.

The read

What is Vaxcyte, Inc.’s financial profile?

Vaxcyte, Inc. earned -$766.6M in FY2025 net income.

Peers · Healthcare

Nuvalent, Inc.——Apogee Therapeutics, Inc.——Immunovant, Inc.——Belite Bio, Inc——Erasca, Inc.——Definium Therapeutics, Inc.——

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Equinix, Inc.$9.2B74B Robinhood Markets, Inc.$4.5B67B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$052D

Key facts

CEOGrant E. Pickering

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Carlos, CA

ExchangeNASDAQ: PCVX

Employees507

IPO date2020-06-12

Latest filings

8-K2026-06-23 8-K2026-06-16 10-Q2026-05-06 8-K2026-05-06 DEF 14A2026-04-23 10-K2026-02-24 8-K2026-02-24 8-K2026-02-24

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.